
Sign up to save your podcasts
Or


In this episode, UROONCO kidney cancer chief editor Dr. Carmen Mir talks to Assoc. Prof. Tian Zhang from UT Southwestern Medical Center (USA). Assoc. Prof. Zhang shares an overview on the trial results of metastatic kidney cancer (mRCC) that were discussed at ASCO GU25. These trials include CheckMate-9ER, COSMIC-313, KEYMAKER-U03, LITESPARK-011. Assoc. Prof. Zhang gives her expert opinion on how these trials could impact clinical practice on first-line kidney cancer treatment.
For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.
By European Association of Urology3.7
33 ratings
In this episode, UROONCO kidney cancer chief editor Dr. Carmen Mir talks to Assoc. Prof. Tian Zhang from UT Southwestern Medical Center (USA). Assoc. Prof. Zhang shares an overview on the trial results of metastatic kidney cancer (mRCC) that were discussed at ASCO GU25. These trials include CheckMate-9ER, COSMIC-313, KEYMAKER-U03, LITESPARK-011. Assoc. Prof. Zhang gives her expert opinion on how these trials could impact clinical practice on first-line kidney cancer treatment.
For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

43,741 Listeners

318 Listeners

499 Listeners

1,423 Listeners

2,445 Listeners

17 Listeners

1 Listeners

144 Listeners

57 Listeners

2 Listeners

3,658 Listeners

53 Listeners

1,675 Listeners

0 Listeners

3 Listeners